Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MATR vs MMSI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MMSI Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

MMSI Overall Winner 6-Pillar Tally: MATR 0 – 5 MMSI (1 Tie) Matrix Metrics: MATR 1 – 9 MMSI

As of Nov 16, 2026, Merit Medical Systems Inc (MMSI) is the stronger overall head-to-head candidate over MATR (MATR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MATR carries a Unified Composite Score of 47.4/100 (HOLD) at $26.23 (N/M Forward P/E, N/A operating margin), whereas MMSI carries 61.4/100 (BUY) at $86.35 (18.5x Forward P/E, 13.9% operating margin).

  • Technical & Structure Timing Caution: MATR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile MMSI is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MATR vs MMSI
MATR US Equity
MATR
Institutional Equity
$26.23
-1.72% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.86β · 19% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
MMSI NASDAQ Head-to-Head Winner
Merit Medical Systems Inc
Surgical & Medical Instruments & Apparatus
$86.35
-0.32% 1D
Market Cap $5.2B
TTM Revenue $1.61B
Forward P/E 18.5x
Beta / 30D Vol 0.49β · 44% Vol
Unified Composite Score
61.4 / 100 BUY
Tech 58.0 Fund 53.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.4%) with fading momentum, RSI 44
RSI-14: 44.2 · SMA20: $89.47 · SMA50: $87.95

6-Pillar Scorecard Institutional Category Breakdown (MATR 0 – 5 MMSI)

Columns: Metric · MATR · MMSI
1. Valuation Multiples MMSI
Forward P/E N/M 18.5x
Trailing P/E N/M 32.5x
PEG Ratio N/M 1.54x
EV / Revenue N/M 3.2x
2. Growth & Scale MMSI
Revenue Growth (YoY) N/A +8.4%
Earnings Growth (YoY) N/A +52.2%
TTM Revenue (USD) N/A $1.61B
Market Cap N/A $5.2B
3. Profitability & Quality MMSI
Gross Margin N/A 49.0%
Operating Margin N/A 13.9%
Net Profit Margin N/A 9.9%
Return on Equity (ROE) N/A 9.8%
4. Balance Sheet & Cash Flow MMSI
Cash Generation (TTM) N/A $349M EBITDA
Cash Flow Margin N/A 21.6% EBITDA Mgn
Net Cash / Leverage N/A ROE $29.12 Book/Sh · 9.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 30.9% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Distribution
6. R&D & Supply-Chain Moat MMSI
OpEx & R&D Intensity N/A 35.1% of Rev ($565M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MATR (1) vs MMSI (9)
Institutional Metric MATR MMSI Criterion Row Edge
Market Capitalization
Scale
N/A $5.2B Larger Scale MMSI
Trailing P/E Ratio
Valuation
N/M 32.5x Lower Multiple MMSI
Forward P/E Ratio
Valuation
N/M 18.5x Lower Multiple MMSI
Revenue Growth (YoY)
Growth
N/A +8.4% Higher Growth MMSI
Operating Margin (TTM)
Profitability
N/A 13.9% Higher Margin MMSI
Net Profit Margin
Profitability
N/A 9.9% Higher Margin MMSI
Return on Equity (ROE)
Capital Efficiency
N/A 9.8% Higher ROE MMSI
52-Week Range Position
Momentum
3% ($26–$28) 76% ($60–$95) Stronger Trend MMSI
Beta / 30D Volatility
Risk Regime
0.86β · 19% Vol 0.49β · 44% Vol Lower Realized Risk MATR
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 61.4 / 100 (BUY) Higher Composite MMSI
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.61B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 49.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.54x PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $349M EBITDA ($29.12 Book/Sh · 9.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MMSI +1.01 pp
MATR: -4.21% · MMSI: -3.2%
3M Horizon MMSI +1.74 pp
MATR: -6.49% · MMSI: -4.75%
6M Horizon MMSI +1.74 pp
MATR: -6.49% · MMSI: -4.75%
1Y Horizon MMSI +1.74 pp
MATR: -6.49% · MMSI: -4.75%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MATR vs MMSI. Trailing 12-month operating profitability (MATR N/A vs MMSI 13.9%) and valuation multiples (MATR N/M vs MMSI 18.5x Forward P/E) are benchmarked directly in Pillar 4 below.

MATR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
MMSI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.61B
Gross Margin49.0%
Op. Margin13.9%
ROE / Fwd P/E9.8% · 18.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MATR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MATR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MMSI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 30.9%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MMSI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MATR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MMSI Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $5.2B market capitalization and 13.9% operating margin.
OpEx & R&D Reinvestment 35.1% of Rev ($565M)
90D Engineering Disclosures 0 Published

Investor FAQ MATR vs MMSI Key Questions & Quantitative Answers

As of Nov 16, 2026, Merit Medical Systems Inc (MMSI) is the stronger overall head-to-head candidate over MATR (MATR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MATR carries a Unified Composite Score of 47.4/100 (HOLD) at $26.23 (N/M Forward P/E, N/A operating margin), whereas MMSI carries 61.4/100 (BUY) at $86.35 (18.5x Forward P/E, 13.9% operating margin). Technical & Structure Timing Caution: MATR trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A); meanwhile MMSI is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MMSI leads the Growth & Scale pillar: MATR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with MMSI at +8.4% YoY revenue growth and +52.2% YoY earnings growth on $1.61B TTM revenue (49.0% gross margin, 13.9% operating margin). On trailing 12-month operating scale, MATR generates N/A in USD-normalized revenue versus $1.61B for MMSI. In operating R&D and SG&A reinvestment, MATR deploys N/A (0 90-day corporate R&D disclosures) versus 35.1% of Rev ($565M) (0 disclosures) for MMSI.

MMSI screens cheaper on headline valuation multiples. MATR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MMSI trades at 18.5x Forward P/E, 32.5x Trailing P/E, 1.54x PEG, and 3.2x EV/Revenue (21.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MATR (N/A ROE) versus MMSI (9.8% ROE) capital efficiency.

In options market volatility and institutional positioning, MATR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.86β · 19% Vol realized risk). By comparison, MMSI carries 30.9% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 44% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.